Vaccines (Feb 2024)

A Practical Guide to Full Value of Vaccine Assessments

  • Caroline Trotter,
  • Birgitte Giersing,
  • Ann Lindstrand,
  • Naor Bar-Zeev,
  • Tania Cernuschi,
  • Lauren Franzel-Sassanpour,
  • Martin Friede,
  • Joachim Hombach,
  • Maarten Jansen,
  • Mateusz Hasso-Agopsowicz,
  • Mitsuki Koh,
  • So Yoon Sim,
  • Dijana Spasenoska,
  • Karene Hoi Ting Yeung,
  • Philipp Lambach

DOI
https://doi.org/10.3390/vaccines12020201
Journal volume & issue
Vol. 12, no. 2
p. 201

Abstract

Read online

Articulating the wide range of health, social and economic benefits that vaccines offer may help to overcome obstacles in the vaccine development pipeline. A framework to guide the assessment and communication of the value of a vaccine—the Full Value of Vaccine Assessment (FVVA)—has been developed by the WHO. The FVVA framework offers a holistic assessment of the value of vaccines, providing a synthesis of evidence to inform the public health need of a vaccine, describing the supply and demand aspects, its market and its impact from a health, financial and economic perspective. This paper provides a practical guide to how FVVAs are developed and used to support investment in vaccines, ultimately leading to sustained implementation in countries. The FVVA includes a range of elements that can be broadly categorised as synthesis, vaccine development narrative and defining vaccine impact and value. Depending on the features of the disease/vaccine in question, different elements may be emphasised; however, a standardised set of elements is recommended for each FVVA. The FVVA should be developed by an expert group who represent a range of stakeholders, perspectives and geographies and ensure a fair, coherent and evidence-based assessment of vaccine value.

Keywords